Dexamethasone showed no clear difference in neurodevelopmental disability at compared with betamethasone – child outcomes (moderate certainty).
Dexamethasone showed no clear difference in visual impairment compared with betamethasone – child outcomes (low certainty).
Dexamethasone showed no clear difference in hearing impairment compared with betamethasone – child outcomes (moderate certainty).
Dexamethasone showed no clear difference in developmental delay –motor (mild, moderate or severe) compared with betamethasone – child outcomes (moderate certainty).
Dexamethasone showed no clear difference in intellectual impairment: developmental delay – cognitive or language… compared with betamethasone – child outcomes (moderate certainty).
Dexamethasone showed no clear difference in cerebral palsy compared with betamethasone – child outcomes (low certainty).
It is very uncertain whether dexamethasone: oral changes any known death after randomisation (fetal, neonatal, child, child… compared with intramuscular – fetal/neonatal outcomes (very low certainty).
It is very uncertain whether dexamethasone: oral changes respiratory distress syndrome compared with intramuscular – fetal/neonatal outcomes (very low certainty).
It is very uncertain whether dexamethasone: oral changes intraventricular haemorrhage compared with intramuscular – fetal/neonatal outcomes (very low certainty).
It is very uncertain whether dexamethasone: oral changes necrotising enterocolitis compared with intramuscular – fetal/neonatal outcomes (very low certainty).
Dexamethasone showed no clear difference in chorioamnionitis compared with betamethasone – maternal outcomes (moderate certainty).
The review found no eligible studies for this question.
It is very uncertain whether betamethasone acetate plus phosphate changes any known death after randomisation (fetal, neonatal, child, child… compared with betamethasone phosphate – fetal/neonatal outcomes (very low certainty).
It is very uncertain whether betamethasone acetate plus phosphate changes respiratory distress syndrome compared with betamethasone phosphate – fetal/neonatal outcomes (very low certainty).
It is very uncertain whether betamethasone acetate plus phosphate changes intraventricular haemorrhage compared with betamethasone phosphate – fetal/neonatal outcomes (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether betamethasone 12‐hourly changes any known death after randomisation (fetal, neonatal, child, child… compared with 24‐hourly dosing – fetal/neonatal outcomes (very low certainty).
It is very uncertain whether betamethasone 12‐hourly changes respiratory distress syndrome compared with 24‐hourly dosing – fetal/neonatal outcomes (very low certainty).
It is very uncertain whether betamethasone 12‐hourly changes intraventricular haemorrhage compared with 24‐hourly dosing – fetal/neonatal outcomes (very low certainty).